Barclays reaffirmed their overweight rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage currently has a £125 ($158.21) target price on the biopharmaceutical company’s stock. Several other equities analysts also recently commented on the stock. Deutsche Bank Aktiengesellschaft reissued a […]
While AstraZeneca CEO Pascal Soriot's proposed pay package has attracted
In a shot in the arm for the FTSE 100 group, a trial revealed that Imfinzi showed promise in treating highly aggressive small cell lung cancer.
For most CEOs in the U.K., a salary exceeding $20 million is the stuff of